| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | cap5A |
| Uniprot No | P95695 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-222aa |
| 氨基酸序列 | MESTLELTKIKEVLQKNLKILIILPLLFLIISAIVTFFVLSPKYQANTQILVNQTKGDNPQFMAQEVQSNIQLVNTYKEIVKSPRILDEVSKDLNDKYSPSKLSSMLTITNQENTQLINIQVKSGHKQDSEKIANSFAKVTSKQIPKIMSVDNVSILSKADGTAVKVAPKTVVNLIGAFFLGLVVALIYIFFKVIFDKRIKDEEDVEKELGLPVLGSIQKFN |
| 预测分子量 | 26.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于cap5A重组蛋白的3篇参考文献示例(注：文献信息为模拟虚构，仅供格式参考)：
1. **《Expression and immunogenicity of recombinant Cap5A from Staphylococcus aureus》**
- 作者：Lee, J. et al.
- 摘要：研究通过大肠杆菌系统成功表达并纯化Cap5A重组蛋白，动物实验显示其能诱导高水平抗体，显著增强小鼠对金黄色葡萄球菌感染的抵抗力。
2. **《Structural characterization of Cap5A and its role in bacterial pathogenesis》**
- 作者：Zhang, R. & Smith, T.
- 摘要：通过X射线晶体学解析Cap5A蛋白的三维结构，揭示其与宿主细胞相互作用的分子机制，为靶向该蛋白的抗菌药物设计提供依据。
3. **《Cap5A as a potential vaccine candidate against Staphylococcus aureus infections》**
- 作者：Wang, H. et al.
- 摘要：评估Cap5A重组蛋白联合佐剂的免疫效果，证明其可触发Th1/Th2混合免疫应答，并在多血清型感染模型中展现交叉保护潜力。
*提示*：实际文献需通过PubMed/Google Scholar等平台检索关键词(如“Cap5A recombinant”、“Staphylococcus aureus capsule 5A”)。建议结合具体研究方向筛选高相关度论文。
**Background of Cap5A Recomcombinant Protein**
*Staphylococcus aureus*, a Gram-positive pathogen, is a major cause of hospital- and community-acquired infections, ranging from mild skin conditions to life-threatening sepsis. Its virulence is partly attributed to surface-associated structures, including capsular polysaccharides (CPs), which protect the bacterium from host immune defenses. Among 11 known CP serotypes, serotype 5 (CP5) is prevalent in clinical isolates and linked to invasive diseases. The *cap5* operon encodes enzymes and regulatory proteins required for CP5 biosynthesis, with Cap5A being a critical component.
Cap5A is a membrane-associated protein involved in the polymerization or translocation of CP5 subunits across the bacterial cell wall. Studies suggest it may act as a glycosyltransferase or a polysaccharide chain-length determinant, facilitating the assembly of the CP5 capsule. Recombinant Cap5A protein, produced via heterologous expression systems (e.g., *E. coli*), enables structural and functional studies to dissect its role in virulence.
Research on recombinant Cap5A aims to:
1. **Elucidate pathogenesis mechanisms**: Understanding its interaction with host cells and immune evasion strategies.
2. **Develop therapeutics**: CP5 is a vaccine candidate; Cap5A-specific antibodies could neutralize bacterial encapsulation.
3. **Combat antibiotic resistance**: Targeting CP5 biosynthesis may enhance antimicrobial efficacy.
Recent advances in structural biology and immunology have highlighted Cap5A's potential as a diagnostic or prophylactic target. However, challenges remain, including clarifying its enzymatic activity and optimizing its immunogenicity in vaccine formulations. Ongoing studies continue to explore its applications in novel anti-*S. aureus* strategies.
×
